文献速递临床生化临床免疫

sFlt-1/PlGF比值用于排除需终止妊娠的子痫前期:证据可重复吗?

Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible?
PubMed 文献 · Clin Chem Lab Med · 2018-01-01

该研究纳入195例疑似子痫前期孕妇,在产科分诊或高危门诊就诊时用Cobas e601电化学发光法检测血清sFlt-1与PlGF并计算比值,仅取首次检测结果,由独立产科医生判定最终结局。结果显示sFlt-1/PlGF比值≤38可排除随后1周内因子痫前期终止妊娠,阴性预测值为99.1%。

要点

  • sFlt-1/PlGF比值≤38排除1周内因子痫前期终止妊娠的阴性预测值为99.1%。
  • 24–34周单胎妊娠首次比值≤38者中,76例无一因早发型子痫前期分娩。
  • 比值>38预测4周内终止妊娠的阳性似然比与已发表证据相当。

核心结论

  • 在24–34周单胎妊娠且有子痫前期征象者中,首次sFlt-1/PlGF比值≤38时无需再次检测即可完全排除早发型子痫前期。

研究设计与样本

  • 前瞻性观察研究,纳入195例疑似子痫前期的孕妇,于产科分诊入院或高危妊娠门诊留取血样。
  • 血清PlGF与sFlt-1采用Cobas e601免疫分析仪电化学发光免疫分析法(ECLIA)测定并计算比值。
  • 最终结局由独立产科医生复核,仅纳入首次检测结果。

主要发现

  • sFlt-1/PlGF比值≤38排除随后1周内因子痫前期终止妊娠,阴性预测值99.1%,灵敏度97.1%,特异度67.5%。
  • 24–34周首次比值≤38的76例妊娠中,无一例因早发型子痫前期分娩。
  • 比值>38预测4周内因子痫前期终止妊娠的阳性似然比与已发表证据相当。

关键数值与推荐

  • 排除1周内因子痫前期终止妊娠的阈值为sFlt-1/PlGF比值≤38。
  • 该阈值的阴性预测值99.1%、灵敏度97.1%、特异度67.5%。
  • 24–34周首次比值≤38的76例中无早发型子痫前期分娩。

临床怎么用

  • 对24–34周有子痫前期征象的单胎孕妇,首次sFlt-1/PlGF比值≤38可排除早发型子痫前期,无需重复检测。
  • 该策略有助于降低成本并推动sFlt-1/PlGF比值在临床疑似子痫前期孕妇中的应用。

局限性

  • 结论需进一步验证后才能推广。
  • 仅采用首次检测结果,未评估后续检测的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) ratio has been proven to predict preeclampsia occurrence. METHODS: Blood samples from 195 pregnant women with suspected preeclampsia were obtained at obstetric triage admission or from the high-risk pregnancy outpatient office. Serum PlGF and sFlt-1 were measured by an electrochemiluminescence immunoassay (ECLIA) on the immunoanalyser Cobas e601 (Roche Diagnostics) and the corresponding ratio was calculated. Final outcomes were reviewed by an independent obstetrician. Only the first determination was considered. RESULTS: A sFlt-1/PlGF ratio of 38 or lower ruled out the need for pregnancy termination due to preeclampsia in the subsequent week with a negative predictive value (NPV) of 99.1% (sensitivity 97.1% and specificity 67.5%). None of the 76 pregnancies with first determination of an sFlt-1/PlGF ratio of 38 or lower between 24 and 34 weeks of gestation delivered due to early-onset preeclampsia. Positive likelihood ratio (PLR) of an sFlt-1/PlGF ratio above 38 for prediction of pregnancy termination due to preeclampsia within 4 weeks is analogous to published evidence. CONCLUSIONS: Between 24 and 34 weeks of gestation, no subsequent determination was needed to completely rule out early-onset preeclampsia when the first sFlt-1/PlGF ratio determination was 38 or lower in singleton pregnancies with signs or symptoms of this syndrome. These findings, if confirmed, will reduce costs and facilitate the implementation of the sFlt-1/PlGF ratio in women with clinical suspicion of preeclampsia in the third trimester.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Sabrià E, Lequerica-Fernández P, Ganuza PL, et al. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible? Clin Chem Lab Med. 2018. PMID: 28841572. doi:10.1515/cclm-2017-0443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。